Valeant Pharmaceuticals International Inc (VRX): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Valeant Pharmaceuticals International ( VRX) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 2.1%. By the end of trading, Valeant Pharmaceuticals International rose $3.80 (2.9%) to $136.60 on average volume. Throughout the day, 1,139,576 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1,173,600 shares. The stock ranged in a price between $134.00-$136.99 after having opened the day at $134.51 as compared to the previous trading day's close of $132.80. Other companies within the Drugs industry that increased today were: Geron Corporation ( GERN), up 23.6%, Corcept Therapeutics ( CORT), up 22.7%, Alexion Pharmaceuticals ( ALXN), up 21.1% and Prana Biotechnology ( PRAN), up 20.5%.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $44.2 billion and is part of the health care sector. Shares are up 13.1% year to date as of the close of trading on Wednesday. Currently there are 9 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally higher debt management risk.

On the negative front, KaloBios Pharmaceuticals ( KBIO), down 28.4%, Lifevantage Corporation ( LFVN), down 6.2%, AVEO Pharmaceuticals ( AVEO), down 5.7% and Alimera ( ALIM), down 5.5% , were all laggards within the drugs industry with Eli Lilly and Company ( LLY) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Stocks Dive Globally as U.S.-China Trade War Intensifies

Stocks Dive Globally as U.S.-China Trade War Intensifies

Global Oil Prices Mixed as OPEC Production Talks, China Tariffs Weigh on Markets

Global Oil Prices Mixed as OPEC Production Talks, China Tariffs Weigh on Markets

Cryptocurrencies Could 'Bring the Internet to a Halt', Central Bank Agency Warns

Cryptocurrencies Could 'Bring the Internet to a Halt', Central Bank Agency Warns

Volkswagen's Audi CEO Arrested in Diesel Emissions Probe

Volkswagen's Audi CEO Arrested in Diesel Emissions Probe

China Trade War, Google, JD.com, Tesla, Brooks Koepka - 5 Things You Must Know

China Trade War, Google, JD.com, Tesla, Brooks Koepka - 5 Things You Must Know